REVIVA PHARMACEUTCLS HLDGS I

Historical 13F Holders

Symbol
RVPH
CUSIP
76152G209
All holders as of
Q2 2026
Type
Equity
Class
COM NEW
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 76152G209 since 12/18/2024, newest first.

Filer % of Class Filed
Barclays PLC 13G/A Amendment 1 0% 8/13/2026
Event 6/30/2026
Integrated Core Strategies (US) LLC 13G/A Amendment 1
8.2% 8/3/2026
Event 6/30/2026
UBS Group AG 13G/A Amendment 1 0% 7/31/2026
Event 6/30/2026
CVI Investments, Inc. 13G/A Amendment 1
4.9% 5/15/2026
Event 3/31/2026
Barclays PLC 13G 6.0% 5/14/2026
Event 3/31/2026
UBS Group AG 13G 5.8% 5/7/2026
Event 3/31/2026
Integrated Core Strategies (US) LLC 13G
6.2% 3/30/2026
Event 3/23/2026
CVI Investments, Inc. 13G
5.2% 3/25/2026
Event 3/18/2026
Parag Saxena 13D/A Amendment 13 2.8% 3/24/2026
Event 3/20/2026

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 1 1.00 $0
2026 Q2 5 7.73 k $3.67 k
2026 Q1 37 2.92 M $2.13 M
2025 Q4 1 129 k $44.0 k